---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-162755"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2026-04-20T23:59:59+00:00"
generated_at: "2026-05-15T05:23:26.259319+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Kyverna Phase 2 miv-cel data shows 100% response rate at 24 weeks in gMG; durable to 52 weeks

## Summary
- 100% of 7 patients achieved ≥3-point reduction in MG-ADL and QMG (co-primary endpoints) at 24 weeks; mean reductions -8.5 and -11.3 points.
- 57% of patients achieved minimal symptom expression (MG-ADL 0 or 1) at last follow-up; responses deepened over time.
- 100% were free of nonsteroidal immunosuppressants, high-dose steroids, and FcRn/complement inhibitors through Week 24.
- No high-grade CRS or ICANS; two transient grade 3/4 neutropenia events resolved; safety supports outpatient administration.
- Median follow-up 10.2 months (range 3.3–16.0); company enrolling Phase 3 registrational trial across 14 sites.

## SEC filing metadata
- accession: 0001193125-26-162755
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2026-04-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000119312526162755/0001193125-26-162755-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000119312526162755/kytx-20260420.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-162755
- JSON: https://secwatch.observer/filing/0001193125-26-162755.json
- Plain text: https://secwatch.observer/filing/0001193125-26-162755.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.